盐酸伊托必利与瑞巴派特联用治疗慢性萎缩性胃炎的研究OA

Objective Based on clinical practice experience,this study explores the clinical efficacy and safety of itopride hydrochloride dispersible tablets combined with rebamipide tablets in the treatment of Chronic Atrophic Gastritis(CAG).Methods A total of 146 patients diagnosed with CAG through gastroscopy in our hospital from September 2021 to March 2024 were selected as the research subjects.According to the envelope method,the patients were randomly divided into an observation group and a control group.The control group was treated with itopride hydrochloride dispersible tablets,while the observation group additionally received combi-nation therapy with rebamipide tablets..Compare the differences in the expression of inflammatory factors,gastrointestinal hormones,gastric mucosal recovery indicators,intestinal microbiota,and gastroscopy performance scores between two groups of patients.Results After treatment,all endoscopic scores in both groups showed a significant decrease compared to before treatment(P<0.05).Addition-ally,in the observation group,the degree of intestinal metaplasia,gastric atrophy,and gastric mucosal feature scores were lower than those in the control group(t-intestinal metaplasia=15.081,t-gastric mucosal features=10.181,t-gastric atrophy=16.045,P<0.05).Post-treatment,the expression levels of EGF and NO in both groups were significantly higher than before treatment(P<0.05),and the observation group exhibited significantly higher EGF and NO expression levels than the control group(P<0.05).After treat-ment,IL-6 and TNF-αlevels in the observation group were significantly lower than those in the control group(P<0.05).The MTL level in the observation group was significantly lower than that in the control group(P<0.05),while GAS and G-17 levels were signifi-cantly higher(P<0.05).Post-treatment,the counts of intestinal Bifidobacteria and Lactobacilli significantly increased in both groups compared to before treatment.The observation group showed significantly higher counts of Bifidobacteria and Lactobacilli than the con-trol group,while the counts of Staphylococci and Enterococci decreased,with the observation group displaying lower levels than the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of itopride hydrochloride and rebamipide is safe and effective in treating CAG,and can sig-nificantly improve both endoscopic and histopathological findings in patients.